DrugPatentWatch

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Clinical Trials for: KALETRA

First 100 trials shown — repeat this search at ClinicalTrials.gov

TitleStatusConditionLast ChangedExternal link
Comparison of Liquid Kaletra and Low Dose Kaletra Tablets Completed HIV Infections February 5, 2014 link
Lopinavir Capsules to Kaletra or Invirase Tablets Completed HIV Infections July 15, 2011 link
KONCERT A Kaletra ONCE Daily Randomised Trial of the Pharmacokinetics, Safety and Efficacy of Twice-daily Versus Once-daily Lopinavir/Ritonavir Tablets Dosed by Weight as Part of Combination Antiretroviral Therapy in Human Immunodeficiency Virus-1 (HIV-1) Infected Children (PENTA 18) Completed Antiretroviral Therapy in HIV-1 Infected Children October 25, 2013 link
Lopinavir/Ritonavir (Kaletra) PK in Children Completed HIV/AIDS Treatment; HIV Infections June 2, 2012 link
Drug-drug Interaction Study Between Lopinavir/Ritonavir and Isavuconazole Completed Pharmacokinetics of Isavuconazole; Pharmacokinetics of Lopinavir/Ritonavir; Healthy Volunteers November 7, 2012 link
Efficacy and Safety of Kaletra Monotheraphy Compared to Kaletra Based Triple Therapy to Treat HIV in Antiretroviral Naїve Patients Completed HIV Infection April 1, 2008 link
A Comparison Study of Kaletra Soft-Gel Capsules and Kaletra Tablets in an African American Cohort Completed HIV-1; AIDS April 4, 2007 link
Efficacy of Simplified Two Drug Kaletra Regimen vs. Kaletra Triple Drug Standard of Care Regimen in Treatment naïve HIV Infected Patients Completed HIV Infection July 9, 2008 link
Evaluation of Kaletra Therapy Over the Long-term Completed Human Immunodeficiency Virus August 9, 2011 link
GSK706769/KALETRA Drug-drug Interaction Study Completed Healthy Subjects; Infection, Human Immunodeficiency Virus June 21, 2012 link
The Effect of Pregnancy on the Pharmacokinetics of the Kaletra Tablet Completed Pregnancy; HIV May 11, 2011 link
Drug Use Investigation of Kaletra Completed Human Immunodeficiency Virus January 31, 2012 link
Study on the Effect of Kaletra + Nevirapine as Maintenance Bitherapy Compared to a Triple Therapy Including Kaletra + Analogues in HIV Patients Completed HIV Infections February 19, 2008 link
Special Investigation of Kaletra in Pregnant Women Completed Human Immunodeficiency Virus December 9, 2011 link
Lopinavir (LPV) Dose Reduction Completed HIV-1 Infections July 8, 2010 link
Pharmacokinetic Interactions Between Buprenorphine and Kaletra (Lopinavir/Ritonavir) Completed HIV Infections October 19, 2012 link
Study Comparing Lopinavir/Ritonavir (LPV/r) + Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) With a Nucleoside Sparing Regimen Consisting of Lopinavir/Ritonavir + Raltegravir (RAL) Completed Human Immunodeficiency Virus Infection February 13, 2012 link
Pharmacokinetics of the Tablet Formulation of Lopinavir/r as Standard and Increased Dosage During Pregnancy Completed HIV Infections; Pregnancy October 25, 2013 link
Drug Interaction Study Between Lumefantrine and Lopinavir/Ritonavir Completed HIV Infections December 3, 2010 link
Clinical, Virological and Safety Outcomes of a Lopinavir/Ritonavir-Based Regimen in HIV-1 Infected Patients in Routine Clinical Use in China Completed HIV-1 Infections July 7, 2011 link
Kaletra Monotherapy in HIV/HCV Co-infected Subjects Completed HIV Infections May 28, 2012 link
ROCKET II - Randomized Open Label Switch for Cholesterol Elevation on Kivexa + Kaletra Evaluation Trial Completed HIV-1 November 18, 2011 link
Clinical Study of an Aluvia-based HAART Regimen for Prevention of Mother-to-child HIV Transmission in Africa Active, not recruiting HIV March 16, 2010 link
Raltegravir Kaletra Pharmacokinetics Completed Healthy June 16, 2008 link
Pilot Simplification Study to Lopinavir/Ritonavir 800/200 mg Monotherapy Regimen Once Daily Recruiting HIV April 19, 2013 link
Safety of Lopinavir/Ritonavir (Kaletra) in HIV/HCV Co-infected Subjects vs Baseline Liver Biopsy Metavir Score Completed HIV Infection January 2, 2013 link
Kaletra and Viread in Antiretroviral Naïve Patients Terminated HIV Infections October 9, 2012 link
Metabolic Effects of Switching Kaletra to Boosted Reyataz Completed HIV Infections March 5, 2010 link
Safety and Effectiveness of World Health Organization Dosing Guidelines of Lopinavir/Ritonavir for Children Completed HIV July 7, 2014 link
Pharmacokinetic Study of Super-boosted Lopinavir/Ritonavir Given With Rifampin Not yet recruiting AIDS; Tuberculosis July 3, 2014 link
Dose Reduction of Lopinavir in Children Completed HIV Infections April 22, 2009 link
Safety and Efficacy of Kaletra in ARV Therapy Experienced Patients Completed Human Immunodeficiency Virus March 14, 2013 link
Kaletra-isentress Treatment Evaluation Completed HIV Infections November 8, 2013 link
Drug Interaction Study of Lopinavir/Ritonavir and Gemfibrozil Completed Healthy Volunteers March 13, 2012 link
Pilot Study of Effect of Kaletra on CD4 Response in HIV Positive (+) Patients With Viral Suppression KIMBO Study Recruiting HIV October 8, 2008 link
Kaletra and Maraviroc in Antiretroviral Therapy (ART)-Naive Patients (KALMAR Study) Terminated HIV Infections June 5, 2014 link
Pharmacokinetic Study of Two Generic co-Formulations of Lopinavir/Ritonavir for HIV Infected Children (SURF) Completed HIV Infections February 24, 2009 link
Study of Lopinavir/ Ritonavir and Lamivudine Versus Standard Therapy in Naïve HIV-1 Infected Subjects. Completed HIV Infection June 8, 2012 link
Pharmacokinetics of Lopinavir/Ritonavir at Three Different Doses. Completed Acquired Immunodeficiency Syndrome March 2, 2011 link
An Evaluation of the Pharmacological Interaction of Lopinavir/r and Rifampin Recruiting HIV Infection; Tuberculosis June 18, 2009 link
Pharmacokinetics of Generic Lopinavir/Ritonavir in Pregnant Women Completed HIV Infections April 3, 2012 link
A Simplified Kaletra® (Lopinavir/Ritonavir)-Based Therapy Versus a Sustiva® (Efavirenz)-Based Standard of Care in Previously Non-Treated HIV-Infected Subjects Completed HIV Infections September 28, 2006 link
Maintenance Boosted Lopinavir Monotherapy Following Salvage Protease-inhibitor (PI) Based Regimen in HIV With Non-nucleoside Reverse Transcriptase Inhibitors (NNRTI) Based Regimen Failure Completed HIV; AIDS; Lopinavir; Treatment Failure May 10, 2013 link
A Pilot Study of Kaletra and Intelence Tablets in Naive Subjects Recruiting HIV Infections February 12, 2010 link
High Dose Ritonavir/Lopinavir Liquid Formulation in Salvage Therapy for Protease Inhibitor Resistant HIV Disease Recruiting HIV; AIDS September 18, 2006 link
Study of Lopinavir/Ritonavir Tablets Comparing Once-Daily Versus Twice-Daily Administration When Coadministered With Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Antiretroviral-Experienced Human Immunodeficiency Virus Type 1 Infected Subjects Completed Human Immunodeficiency Virus Infections April 7, 2011 link
Multicountry, Multicenter Post-Marketing Observational Study of Clinical, Biological and Virological Outcomes, Compliance and Tolerability of Kaletra® in Routine Clinical Use Completed HIV-1 Patients October 10, 2011 link
Study of the 48-Week Virologic and Immunologic Response to Lopinavir/Ritonavir (Kaletra) in HIV Positive Adult Patients Recruiting HIV Infections July 18, 2005 link
Treatment of HIV/HCV Coinfection With Peg-IFN and Ribavirin in Patients Receiving ART Monotherapy With Lopinavir/r Completed HIV/HCV Co-infection; HIV Infections March 21, 2013 link
MK0518 in the Treatment of HIV-Infected Patients Switched From a Protease Inhibitor Regimen (0518-032)(TERMINATED) Terminated HIV Infection February 28, 2012 link
Treatment Perception of QD (Once a Day) Dosed Kaletra (Tablets) Completed Human Immunodeficiency Virus Infection April 30, 2013 link
Lopinavir/r Monotherapy Versus Abacavir/Lamivudine and Lopinavir/r for Limb Fat Recovery in Persons With Lipoatrophy Completed HIV Infection; Lipodystrophy; HIV Infections March 21, 2013 link
Lopinavir/Ritonavir (LPV/r) Tablet in HIV Infected Children Recruiting HIV-1 Infection February 3, 2011 link
Study of Lopinavir/Ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, When Coadministered With Nucleoside Reverse Transcriptase Inhibitors in Antiretroviral Naive Human Immunodeficiency Virus Type 1 Infected Subjects Completed Human Immunodeficiency Virus Infections February 3, 2012 link
Prevention of Lipoatrophy in Patients Treated With Lopinavir/Ritonavir in Monotherapy Versus ZDV + 3TC + ABC Completed HIV Infection; HIV Infections September 11, 2013 link
Pharmacokinetic Interactions Between an Herbal Medicine (African Potato) and Antiretroviral Agents (Lopinavir/Ritonavir) Active, not recruiting Drug Interactions; Human Immunodeficiency Virus May 28, 2013 link
Safety Study of Lopinavir/Ritonavir With Raltegravir in HIV-infected Patients Completed HIV Infections July 19, 2011 link
Ritonavir-boosted Lopinavir Monotherapy Completed HIV November 10, 2011 link
A Bioavailability Study of Rifabutin and Lopinavir/Ritonavir in Healthy Adult Subjects Terminated HIV; Tuberculosis October 29, 2010 link
Prevention of HIV1 Mother to Child Transmission Without Nucleoside Analogue Reverse Transcriptase Inhibitors in the Pre-partum Phase. ANRS 135 Primeva Completed HIV Infections July 17, 2013 link
Trial About Hepatic Security of Antiretroviral Treatment Based on Kaletra Versus Nevirapine in co-Infected HIV/HCV Patients Terminated HIV Infections April 22, 2009 link
A Trial of 2 Options for Second Line Combination Antiretroviral Therapy Following Virological Failure of a Standard Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)+2N(t)RTI First Line Regimen Completed HIV Infections February 12, 2014 link
Analysis of Changes in Adipose Tissue of Patients With Lipoatrophy HIV Infection Treated With Nucleoside Thymidine, After Switching to Monotherapy With Lopinavir / Ritonavir Terminated HIV Infections April 5, 2013 link
Nevirapine vs Ritonavir-boosted Lopinavir in ART Naive HIV-infected Adults in a Resource Limited Setting Completed HIV-1 Infection August 22, 2013 link
GSK1349572 Drug Interaction With Etravirine and Either Darunavir/Ritonavir or Lopinavir/Ritonavir Completed Healthy Volunteer February 20, 2012 link
ABT-378/Ritonavir in Combination With Reverse Transcriptase Inhibitors in Antiretroviral Naïve HIV-Infected Subjects Completed HIV Infections April 2, 2008 link
Seronegatives and Metabolic Abnormalities Protocol 2 (SAMA002): Study to Compare the Effect of Kaletra and Combivir® in HIV-Negative Healthy Subjects Completed HIV Infections; Dyslipidemias; Glucose Metabolism Disorders; Metabolic Diseases; Lipodystrophy; Cardiovascular Disease April 11, 2012 link
Lopinavir/Ritonavir or Efavirenz as First-line Antiretroviral Therapy Active, not recruiting HIV Infections February 12, 2010 link
Kaletra in Combination With Antiretroviral Agents Recruiting Human Immunodeficiency Virus April 10, 2014 link
Evaluation of a Lopinavir/Ritonavir Monotherapy vs a Triple Therapy as Maintenance Regimens in HIV-1 Infected Patients Completed HIV Infections June 23, 2014 link
Immune Reconstitution of Lopinavir/Ritonavir-Based vs Efavirenz-based HAART in Advanced HIV Disease Terminated Acquired Immune Deficiency Syndrome May 30, 2014 link
Pharmacokinetic Study of Two HIV Protease Inhibitors in Patients Terminated HIV Infection February 5, 2009 link
Highly Active Antiretroviral Therapy for Patients With Primary Biliary Cirrhosis Active, not recruiting Primary Biliary Cirrhosis November 11, 2013 link
A Research Study to See if a Change in Therapy for HIV Infection Can Improve the Immune Response to Treatment Completed HIV Infections August 23, 2013 link
Kaletra Sex/Gender Pharmacokinetics (PK) Study Completed HIV Infections November 8, 2013 link
GW873140 In Combination With Kaletra In HIV Infected Subjects Terminated Human Immunodeficiency Virus I Infection; HIV Infection March 17, 2011 link
Four-Drug Combination Treatment in Hiv-Infected Subjects Failing Therapy With Antiretroviral Regimens Completed HIV Infections October 5, 2007 link
Abacavir/Lamivudine Versus Emtricitabine/Tenofovir Both In Combination With Lopinavir/Ritonavir For The Treatment Of HIV Completed HIV Infection June 3, 2010 link
Pilot Assessment of Lopinavir/Ritonavir and Maraviroc Recruiting HIV Infections; Acquired Immunodeficiency Syndrome February 22, 2010 link
TDM of Generic Lopinavir/Ritonavir 200/50 mg Active, not recruiting HIV November 30, 2010 link
Raltegravir + Lopinavir/Ritonavir or Emtricitabine/Tenofovir for HIV Treatment Naive Subjects Completed HIV Infections June 2, 2014 link
KALETRA Or LEXIVA With Ritonavir Combined With EPIVIR And Abacavir In Naive Subjects Over 48 Weeks Completed HIV Infection; Infection, Human Immunodeficiency Virus May 12, 2011 link
BOOST: Study of Increased Dosage of Lopinavir/Ritonavir (LPV/r) Terminated HIV Infections December 6, 2010 link
Safety and Effectiveness of Lopinavir/Ritonavir in Individuals Who Have Failed Prior HIV Therapy Completed HIV Infections August 23, 2012 link
A Study Exploring an Induction-Maintenance Kaletra-Based Therapy Versus a Sustiva-Based Regimen in Previously Non-Treated, HIV-1/HCV Co-Infected Subjects Withdrawn HIV Infection; Hepatitis C July 26, 2006 link
GEMINI Study - A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 Infection Completed HIV Infections September 23, 2011 link
Raltegravir + Lopinavir/Ritonavir Versus Efavirenz + Tenofovir + Emtricitabine in Treatment Naive Patients Completed HIV Infections March 31, 2014 link
Drug Interaction Study Between Eltrombopag and Lopinavir/Ritonavir in Healthy Adult Subjects. Completed Hepatitis C; Thrombocytopenia April 7, 2011 link
Study of Adherence Effects and Clinical Outcomes of Kaletra Based HIV Antiviral Therapy Terminated HIV Infection November 19, 2008 link
Evaluation of the Public Health Interest of Kaletra: Impact on Resistance to Antiretrovirals (ARVs) Completed HIV Infection December 13, 2011 link
Lopinavir and Ritonavir in Improving Immune Response to Vaccines in Patients With Complete Remission Following A Bone Marrow Transplant for Hodgkin Lymphoma Withdrawn Hodgkin Lymphoma; Stage I Adult Hodgkin Lymphoma; Stage II Adult Hodgkin Lymphoma; Stage III Adult Hodgkin Lymphoma; Stage IV Adult Hodgkin Lymphoma March 24, 2014 link
Differences in Blood Levels of Lopinavir/Ritonavir in HIV Infected Men and Women Completed HIV Infections December 4, 2013 link
Drug Interactions of Echinacea, Ginseng, and Ginkgo Biloba Taken With Lopinavir/Ritonavir in Healthy Volunteers Completed Healthy March 13, 2012 link
Ritonavir and Lopinavir in Treating Patients With Progressive or Recurrent High-Grade Glioma Terminated Brain Tumor; Anaplastic Astrocytoma; Anaplastic Ependymoma; Anaplastic Oligodendroglioma; Brain Stem Glioma; Giant Cell Glioblastoma; Glioblastoma; Gliosarcoma; Mixed Glioma April 24, 2013 link
Comparison of Efficacy and Safety of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding Completed HIV Infections April 11, 2014 link
A Multicenter Study to Assess the Tolerability of Once Daily Lopinavir/Ritonavir (LPV/r) Liquid Versus Capsules Completed HIV Infection September 10, 2013 link
Effect of the HIV Protease Inhibitors Atazanavir and Lopinavir/Ritonavir on Cardiovascular Disease Risk Factors Completed Endothelial Dysfunction August 29, 2008 link
Raltegravir vs. Lopinavir/Ritonavir, Both in Combination With Truvada, in HIV+ Treatment Naive Individuals Completed HIV Infections July 7, 2011 link
Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in HIV Recruiting HIV Infection; Tuberculosis June 5, 2014 link
Pediatric Study for Appropriate Dose of Ritonavir Boosted Lopinavir in Thai HIV-infected Children (PEARL) Active, not recruiting HIV-infected Children July 24, 2012 link

Source: ClinicalTrials.gov

This preview shows a limited data set. Complete access is available with a Subscription

« Back to Dashboard

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc